微創機器人-B:2023年度報告
MEDBOT-B: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2023
Changes in Hong Kong stocks | Medical device stocks rose higher in the afternoon, and mining affected the industry's high-value consumables business growth expectations this year generally improved
Medical device stocks rose in the afternoon. As of press release, Weigao shares (01066) rose 9.25% to HK$5.08; Elken Healthcare (01,789) rose 4.35% to HK$4.08; and minimally invasive robot-B (02252) rose 1.91% to HK$13.88.
Minimally Invasive Robot-B (02252.HK) plans to hold a board meeting on March 27 to consider and approve the annual results
Gelonghui March 15 | Minimally Invasive Robot-B (02252.HK) announced that the company will hold a board meeting on March 27, 2024 (Wednesday) to consider and approve, including the Group's annual results for the year ended December 31, 2023, the proposed final dividend (if any), and other matters.
MEDBOT-B: DATE OF BOARD MEETING
Guojin Securities: Medical equipment updates are expected to accelerate demand for high-end innovative medical equipment is expected to be released
It is recommended to focus on segments such as surgical robotics, endoscopes, ultrasound, and ICU equipment.
Hong Kong Stock Concept Tracking | Policies Promote Large-scale Equipment Renewal Agencies to Pay Attention to Medical Equipment Procurement Needs (with concept stocks)
On March 1, the Executive Meeting of the State Council reviewed and approved the “Action Plan to Promote Large-scale Equipment Renewal and Trade-in of Consumer Goods”, which proposed “promoting the orderly upgrading of equipment, transportation equipment, and old agricultural machinery, education and medical equipment in key industries.” The equipment update focuses on the field of “building diplomatic relations between workers and agriculture, education, culture and medicine”. The investment scale was about 6 trillion yuan in '27, with an additional investment of about 300 billion dollars every year, focusing on key industries such as metals, chemicals, building materials, electricity, machinery, transportation, textiles, and electronics. Financial support includes subsidies, tax incentives, and reloan interest rates. According to “Chinese Medical Devices
Changes in Hong Kong stocks | Minimally Invasive Robot-B (02252) rose nearly 20% in the intraday period, annual revenue increased 3.5 times, Tumai Robotics completed its first overseas operation
Minimally invasive robot-B (02252) rose nearly 20% in the intraday period. As of press release, it was up 15.7% to HK$15.18, with a turnover of HK$6.086 million.
Changes in Hong Kong stocks | Minimally Invasive Robot-B (02252) rose more than 16%, and annual revenue is expected to increase by more than 350% year-on-year, and losses narrow to a maximum of 1.05 billion yuan
Minimally invasive robot-B (02252) rose more than 16%. As of press release, it rose 12.92% to HK$16.08, with a turnover of HK$21.578 million.
Changes in Hong Kong stocks | Minimally Invasive Robot-B (02252) fell by more than 3% and is expected to have a net loss of no more than 1.05 billion yuan last year
Minimally invasive robot-B (02252) fell by more than 3%. As of press release, it was down 3.09% to HK$13.8 million, with a turnover of HK$5.87,800.
Announcement Highlights | NIO's Q4 revenue increased 6.5% year on year to 17.103 billion yuan; Great Wall Motor's February sales increased 4.12% year on year
China Electric Power's combined total electricity sales volume in January was 10.3482 million megawatt-hours, an increase of 41.15% over the previous year; Shanghai Pharmaceutical: Norepinephrine bitartrate injection passed the generic drug consistency evaluation.
Minimally Invasive Robot-B (02252.HK) expects revenue growth of more than 350% year-on-year in 2023
Gelonghui, March 5 | Minimally Invasive Robot-B (02252.HK) announced that in the face of a complex and changing external environment, in 2023, the Group will adhere to a business-focused strategy with the primary goal of promoting sustainable business growth, and continuously and thoroughly improve operational efficiency. With extensive multi-track layout, excellent product performance and industry-leading commercialization strength, the Group's many listed products have made significant progress in domestic commercialization breakthroughs and global expansion. The Board of Directors expects the company's revenue for the year ended December 31, 2023 to increase more than year-on-year over the year ended December 31, 2022
Zheshang Securities: What are the marginal changes and investment logic of the pharmaceutical sectors in 2023Q4?
The Zhitong Finance App learned that against the backdrop of high base figures for some products in the 2022 Q4 and 2023Q1 pharmaceutical sector, the bank is more optimistic about digesting undervaluation and investment opportunities with the logic of going overseas.
Changes in Hong Kong stocks | Minimally Invasive Robot-B (02252) is now up more than 4%, R-ONE surgical robot has been approved for listing, and Tumai Robotics has won multiple bids
Minimally invasive robot-B (02252) is now up more than 4%. As of press release, it has risen 4.02% to HK$17.06, with a turnover of HK$11.896 million.
CITIC Securities: Healthcare Faces Deepening Changes and Focusing on Seven Major Prospects of Industrial Trends
CITIC Securities released a research report saying that in 2023 in the post-pandemic era, the healthcare industry ushered in the harshest anti-corruption storm in nearly 20 years. Combined with frequent biomedical industry policies in recent years, industrial development has ushered in profound changes, and sector valuations and public fund allocations are also at historically relatively low levels.
Hang Seng Healthcare Index rose 1.16%; Hanson Pharmaceuticals (03692) rose 6.61%
Jinwu Financial News | Hang Seng Healthcare Index rose 1.16%. Among the constituent stocks, Metz Health (02415) rose 8.1%, Hanson Pharmaceuticals (03692) rose 6.61%, Lepu Biotech (02157) rose 5.28%, minimally invasive robotics (02252) rose 3.98%, and Ping An Good Doctor (01833) rose 3.31%. The CDB Securities Research Report pointed out that although the short-term pharmaceutical industry has been adjusted due to the overall market situation, the industry has ushered in positive factors and changes in terms of policy, performance, valuation level, and position level. Continue to focus on the main line of innovation that has ushered in positive changes
China Approves Surgical Robot Developed by Microport MedBot-Robocath JV
China's medical products administrator approved the R-ONE Vascular Interventional Surgical Robot developed by Cathbot (Shanghai) Robot, a joint venture between Shanghai Microport MedBot (Group) (HKG:2
Changes in Hong Kong stocks | Minimally Invasive Robot-B (02252) rose more than 5%, and Tumai Robots won more than 15 domestic bids
Minimally invasive robot-B (02252) rose more than 5%. As of press release, it was up 4.81% to HK$19.6, with a turnover of HK$7.164,900.
Guojin Securities: Sector-suppressing factors, clear pharmaceuticals are expected to welcome a major inflection point in the reversal of economic sentiment
The Zhitong Finance app learned that Guojin Securities released a research report saying that after a long period of decline and adjustment, the pharmaceutical sector ushered in a major inflection point from the second half of 2023 to 2024, and various factors such as policy, performance, and chips bottomed out and reversed.
Guoxin Securities's 24-year Pharmaceutical Strategy: Good Timing+High Returns, Positioning the Second Wave of Global Innovation Leaders
Guoxin Securities believes that 2023Q4 is the best time to lay out the pharmaceutical market for the next three years.
No Data